Ubiquitin: Not just a one‐way ticket to the proteasome, but a therapeutic dial to fine‐tune the molecular landscape of disease

• Published in: Clinical and translational medicine Vol. 14; no. 7; pp. e1769 - n/a
• Main Authors: Kim, A. Hyun, Chiknas, P. Murdo, Lee, Robin E. C.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.07.2024; John Wiley and Sons Inc; Wiley
• Subjects: Apoptosis; Cancer; Chronic illnesses; Cytokines; deubiquitylating enzyme; DNA damage; Drugs; Enzymes; FDA approval; Federal regulation; Genes; Growth factors; Humans; Inflammatory diseases; Kinases; Leukemia; Localization; Multiple myeloma; precision medicine; Proteasome Endopeptidase Complex - metabolism; Proteins; Proteolysis; Tumor necrosis factor-TNF; ubiquitin; Ubiquitin - metabolism; ubiquitin modifying enzymes; precision medicine; deubiquitylating enzyme; ubiquitin; ubiquitin modifying enzymes
• ISSN: 2001-1326; 2001-1326
• DOI: 10.1002/ctm2.1769

Recently, there is a rise in studies that recognize the importance of targeting ubiquitin and related molecular machinery in various therapeutic contexts. Here we briefly discuss the history of ubiquitin, its biological roles in protein degradation and beyond, as well as the current state of ubiquitin‐targeting therapeutics across diseases. We conclude that targeting ubiquitin machinery is approaching a renaissance, and tapping its full potential will require embracing a wholistic perspective of ubiquitin's multifaceted roles.